NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01066195,Pemetrexed (ALIMTA) and Gefitinib (IRESSAÂ®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy,https://clinicaltrials.gov/study/NCT01066195,,UNKNOWN,"Pemetrexed was known to be effective to pulmonary adenocarcinoma and gefitinib was known to be more effective to non-small cell lung cancer (NSCLC) patients with clinical characteristics such as adenocarcinoma, never smoker and female.

The investigators try to evaluate which drug (pemetrexed vs gefitinib) is more efficious to NSCLC patients with clinical characteristics such as adenocarcinoma and never smoking history as second- or further-line therapy.",NO,Non-small Cell Lung Cancer,DRUG: iressa|DRUG: alimta,"progression-free survival, 36 months","overall survival, 36 months|objective response rate, 36 months|toxicity, 36 months",,Samsung Medical Center,,ALL,"ADULT, OLDER_ADULT",PHASE3,129,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-04-030,2008-05,2010-10,,2010-02-10,,2010-02-10,"Samsung Medical Center, Seoul, Korea, Republic of",
